menu
    • menu
    [{"orgOrder":0,"company":"Samil Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Samil Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samil Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Samil Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Samil Pharmaceutical","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2026","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samil Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Samil Pharmaceutical \/ Samil Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Samil Pharmaceutical \/ Samil Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Samil Pharmaceutical

    Menu

    Samil Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Samil Pharmaceutical

                            South Korea arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Samil Pharmaceutical

                            South Korea arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa Pharmaceuticals Licenses Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery

                            Details : Through the licensing deal for Clobetasol Propionate, a steroid targeting the Glucocorticoid receptor, the agreement aims to address post-operative inflammation.

                            Product Name : APP13007

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            January 12, 2026

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Samil Pharmaceutical

                            South Korea arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Samil Pharmaceutical

                            South Korea arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers

                            Details : Telmisartan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 19, 2015

                            Lead Product(s) : Telmisartan,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.